Isodicentric duplication of Philadelphia chromosome as a mechanism of resistance to dasatinib in a patient with chronic myeloid leukemia after resistance to imatinib

被引：3
|
作者：
Loglisci, Giuseppina [1 ]
Breccia, Massimo [1 ]
Nanni, Mauro [1 ]
Mancini, Marco [1 ]
De Cuia, Rosa [1 ]
Cannella, Laura [1 ]
Salaroli, Adriano [1 ]
Federico, Vincenzo [1 ]
Serrao, Alessandra [1 ]
Loglisci, Maria Giovanna [1 ]
Santopietro, Michelina [1 ]
Alimena, Giuliana [1 ]
机构：
[1] Sapienza Univ, Dept Cellular Biotechnol & Hematol, Rome, Italy
来源：
LEUKEMIA & LYMPHOMA | 2011年 / 52卷 / 07期
关键词：
BCR-ABL; GENE AMPLIFICATION; EXPRESSION; MESYLATE; THERAPY; ST1571; CELLS;
D O I：
10.3109/10428194.2011.565394
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1372 / 1375
页数：4
相关论文
共 50 条
  • [21] Dynamics of cytogenetic aberrations in Philadelphia chromosome positive and negative hematopoiesis during dasatinib therapy of chronic myeloid leukemia patients after imatinib failure.
    Fabarius, Alice
    Schoch, Claudia
    Mueller, Martin C.
    Erben, Philipp
    Lahaye, Tanja
    Giehl, Michelle
    Frank, Oliver
    Seifarth, Wolfgang
    Hehlmann, Rudiger
    Hochhaus, Andreas
    BLOOD, 2006, 108 (11) : 599A - 600A
  • [22] Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
    Ramchandren, Radhakrishnan
    Schiffer, Charles A.
    BIOLOGICS-TARGETS & THERAPY, 2009, 3 : 205 - 214
  • [23] Philadelphia-negative acute lymphoblastic leukemia in a chronic myeloid leukemia patient receiving dasatinib
    Santos, Fabio P. S.
    Rodrigues, Morgani
    Bley Do Nascimento, Claudia Mac-Donald
    Kerbauy, Fabio R.
    Feitosa Ribeiro, Andreza Alice
    Kutner, Jose Mauro
    Hamerschlak, Nelson
    CYTOTHERAPY, 2010, 12 (01) : 113 - 115
  • [24] Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome-positive chronic myeloid leukemia patients with resistance or intolerance to imatinib
    Cortes, Jorge E.
    Kantarjian, Hagop M.
    Bruemmendorf, Tim H.
    Kim, Dong-Wook
    Turkina, Anna G.
    Shen, Zhi-Xiang
    Pasquini, Ricardo
    Khoury, H. Jean
    Arkin, Steven
    Volkert, Angela
    Besson, Nadine
    Abbas, Richat
    Wang, Junyuan
    Leip, Eric
    Gambacorti-Passerini, Carlo
    BLOOD, 2011, 118 (17) : 4567 - 4576
  • [25] Additional rearrangements affecting the derivative chromosome 9 involved in the standard Philadelphia translocation after imatinib therapy in a patient with chronic myeloid leukemia
    Wang, Huan-Ping
    Chen, Zhi-Mei
    Lou, Ji-Yu
    Xu, Huan
    Yu, Yun-Biao
    Jin, Jie
    CANCER GENETICS AND CYTOGENETICS, 2008, 182 (01) : 63 - 64
  • [26] Mechanism of drug resistance to dasatinib (BMS-354825) and imatinib in chronic myelogenous leukemia cells.
    Okabe, Seiichi
    Tauchi, Tetsuzo
    Broxmeyer, Hal E.
    Ohyashiki, Kazuma
    BLOOD, 2006, 108 (11) : 404A - 404A
  • [27] Response to imatinib in patients with chronic myeloid Leukemia (CML) with variant Philadelphia chromosome (Ph).
    El-Zimaity, MMT
    Kantarjian, HM
    Talpaz, M
    Garcia-Manero, G
    O'Brien, S
    Giles, FJ
    Verstovsek, S
    Ferrajoli, A
    Rios, MB
    Hayes, KJ
    Cortes, JE
    BLOOD, 2002, 100 (11) : 788A - 788A
  • [28] Imatinib-induced thyroiditis in Philadelphia chromosome-positive chronic myeloid leukemia
    Singh, Surjit
    Sharma, Pramod Kumar
    INDIAN JOURNAL OF PHARMACOLOGY, 2016, 48 (04) : 458 - 459
  • [29] Mechanisms of Primary and Secondary Resistance to Imatinib in Chronic Myeloid Leukemia
    Quintes-Cardama, Alfonso
    Kantarjian, Hagop M.
    Cortes, Jorge E.
    CANCER CONTROL, 2009, 16 (02) : 122 - 131
  • [30] Imatinib mesylate noncompliance simulating chronic myeloid leukemia resistance
    Sandoval, C
    Giamelli, J
    Jayabose, S
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2003, 25 (06) : 507 - 508
12345